Avelox (Moxifloxacin, BAY12-8039)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Maxillary Sinusitis
Conditions
Maxillary Sinusitis
Trial Timeline
Jun 1, 2004 → Jan 1, 2005
NCT ID
NCT00668304About Avelox (Moxifloxacin, BAY12-8039)
Avelox (Moxifloxacin, BAY12-8039) is a approved stage product being developed by Bayer for Maxillary Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00668304. Target conditions include Maxillary Sinusitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01690533 | Pre-clinical | Completed |
| NCT00930488 | Pre-clinical | Completed |
| NCT00668304 | Approved | Completed |
Competing Products
5 competing products in Maxillary Sinusitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin | Johnson & Johnson | Phase 3 | 77 |
| Azithromycin SR + Amoxiclav 1000 mg | Pfizer | Pre-clinical | 22 |
| azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin | Pfizer | Phase 3 | 76 |
| Telithromycin | Sanofi | Phase 3 | 76 |
| Azithromycin + Telithromycin | Sanofi | Approved | 84 |